NeuroRx has partnered with leading patient advocacy groups and experts in the bipolar disorder community to launch the 1st global “voice of the patient” survey to gain insights into care received during hospitalization for a suicidal crisis recent hospitalization is a risk factor for further suicide attempts -- potentially related to patient care perceptions

NeuroRx has launched the first global “Voice of the Patient Survey” for those diagnosed with bipolar disorder, in collaboration with leading patient advocacy groups, mental health advocates and expert opinion leaders. The strictly anonymous survey, seeking 1,000 respondents, will allow for a greater understanding of the care people with bipolar disorder received during hospitalization for an acute suicidal crisis or a suicide attempt.


Researchers concur that recent hospitalization for a suicidal attempt is a serious risk factor for further suicidal attempts. While many factors may contribute to this, including the underlying psychiatric condition, little data exists on the patient’s perspective about the care that was received.  This survey seeks, for the first time, to understand where, and what types of care, succeeded, or failed, to meet the patient’s needs through the eyes of those who have experienced the nightmare of suicidal depression.


The International Bipolar Foundation, Hope Xchange, Julie Fast (bipolar advocate and author of “Loving Someone with Bipolar Disorder”), and Natasha Tracy (bipolar advocate and author of “Lost Marbles: Insights into My Life with Depression & Bipolar”), will help launch the survey and encourage the bipolar community to take part in the survey.




Special Thanks to:

International Bipolar Foundation

Visit them at:

Hope Xchange

Visit them at:

Julie Fast

bipolar advocate and author of “Loving Someone with Bipolar Disorder”

Visit her here:

Natasha Tracy

bipolar advocate and author of “Lost Marbles: Insights into My Life with Depression & Bipolar”

Visit her here:

© 2016 NeuroRx, Inc.

*This drug is investigational and not approved by the US FDA